At a glance
- Originator Sanofi-Synthelabo
- Class Antiparkinsonians; Neuroprotectants
- Mechanism of Action Monoamine oxidase B inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Parkinson's disease
Most Recent Events
- 23 May 1995 Discontinued-Preclinical for Parkinson's disease in USA (PO)